Background
A 62-year-old male with a history of hypertension was receiving long-term doxazosin therapy from his cardiologist. A urologist later prescribed tamsulosin for benign prostatic hyperplasia (BPH).
Both medications are alpha-blockers. Taken together, they can create an unnecessary overlap in therapy and increase the risk of hypotension, syncope and additive side effects.
What we did
HyperCare flagged the duplicate therapy, and the PharmPix clinical team acted quickly. The team contacted the cardiologist who prescribed doxazosin; the cardiologist confirmed that doxazosin should be discontinued.
The impact
- Duplicate alpha-blocker therapy was addressed before patient harm occurred
- Risk of hypotension and syncope was reduced
- Prescriber coordination helped clarify the intended treatment plan
Clinical protection happens at the point decisions are made. PharmPix helps identify potential medication risks and brings clinical protection to the moments that matter.
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.
The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.